This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Mexican antitrust agency says generic drug market needs reform to boost competition

( August 9, 2017, 18:20 GMT | Official Statement) -- MLex Summary: The Mexican antitrust authority said in a report that the generic drug market in the country needs reform to become more competitive. The Federal Economic Competition Commission, or Cofece, concluded that regulatory isssues and public policy decisions are inhibiting the entry of new players to the market, and that there are no incentives or pressure for lower prices in the drugs market. According to the report, the entry of generic drugs in the market takes a long time, and generally leads to modest price reductions only after two years. Cofece argues for a regulatory and public policy reform....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections